公开(公告)号：US08097417B2

公开(公告)日：2012-01-17

申请号：US12380103

申请日：2009-02-23

申请人： Liping Zhao ,  Wei Hua ,  Xiaoyan Pang ,  Jia Wei ,  Dazheng Wu

发明人： Liping Zhao ,  Wei Hua ,  Xiaoyan Pang ,  Jia Wei ,  Dazheng Wu

IPC分类号： C12Q1/68 ,  C12P19/34

CPC分类号： C12Q1/6886 ,  C12Q1/6888

摘要： Non-invasive methods for monitoring the effect of an agent for treating colorectal cancer, comprising (1) collecting fecal samples from healthy subjects, subjects having precancerous lesions, and subject having precancerous lesions and being treated with an anti-cancer agent; (2) isolating total microbial genomic DNA from the fecal samples to provide total microbial genomic DNA; (3) comparing the total microbial genomic DNA using fingerprint spectrum analysis; (4) identifying key fingerprint bands correlated with the effect of the anti-cancer agent; (5) identifying key microorganisms associated with the key fingerprint bands; (6) designing microbial sequence-specific primers and probes; and (7) determining the quantitative differences of the key microorganisms in fecal samples to identify an indicator microorganism for monitoring the effect of the anti-cancer agent.

摘要翻译： 用于监测药物治疗结肠直肠癌的效果的非侵入性方法，包括（1）从健康受试者收集粪便样品，患有癌前病变的受试者和患有癌前病变的受试者并用抗癌剂治疗; （2）从粪便样品中分离总微生物基因组DNA以提供总微生物基因组DNA; （3）使用指纹谱分析比较总微生物基因组DNA; （4）识别与抗癌剂作用相关的关键指纹带; （5）识别与关键指纹带相关的关键微生物; （6）设计微生物序列特异性引物和探针; 和（7）确定粪便样品中关键微生物的定量差异，以鉴定用于监测抗癌剂效果的指示剂微生物。

公开(公告)号：US20100112564A1

公开(公告)日：2010-05-06

申请号：US12380103

申请日：2009-02-23

申请人： Liping Zhao ,  Wei Hua ,  Xiaoyan Pang ,  Jia Wei ,  Dazheng Wu

发明人： Liping Zhao ,  Wei Hua ,  Xiaoyan Pang ,  Jia Wei ,  Dazheng Wu

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q1/6888

摘要： precancerous lesions, and subject having precancerous lesions and being treated with an anti-cancer agent; (2) isolating total microbial genomic DNA from the fecal samples to provide total microbial genomic DNA; (3) comparing the total microbial genomic DNA using fingerprint spectrum analysis; (4) identifying key fingerprint bands correlated with the effect of the anti-cancer agent; (5) identifying key microorganisms associated with the key fingerprint bands; (6) designing microbial sequence-specific primers and probes; and (7) determining the quantitative differences of the key microorganisms in fecal samples to identify an indicator microorganism for monitoring the effect of the anti-cancer agent.

摘要翻译： 癌前病变和患有癌前病变并且用抗癌剂治疗的受试者; （2）从粪便样品中分离总微生物基因组DNA以提供总微生物基因组DNA; （3）使用指纹谱分析比较总微生物基因组DNA; （4）识别与抗癌剂作用相关的关键指纹带; （5）识别与关键指纹带相关的关键微生物; （6）设计微生物序列特异性引物和探针; 和（7）确定粪便样品中关键微生物的定量差异，以鉴定用于监测抗癌剂效果的指示剂微生物。